No data to show
XNAS
NAMSW
Market cap2.25bUSD
May 02, Last price
9.24USD
1D
0.11%
1Q
-18.16%
IPO
872.63%
Name
NewAmsterdam Pharma Company NV
Chart & Performance
P/E
—
P/S
20.13
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
46m
+257.00%
Net income
-242m
L+36.54%
CFO
-159m
L+12.28%
Profile
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | |
| Income | |||||
Revenues | 45,563 257.00% | 12,763 -86.69% | 95,906 | ||
Cost of revenue | 221,852 | 189,195 | 82,606 | ||
Unusual Expense (Income) | |||||
NOPBT | (176,289) | (176,432) | 13,300 | ||
NOPBT Margin | 13.87% | ||||
Operating Taxes | (1,000) | 27 | |||
Tax Rate | |||||
NOPAT | (176,288) | (176,459) | 13,300 | ||
Net income | (241,598) 36.54% | (176,937) 737.06% | (21,138) -42.42% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 645,507 | 7,337 | 377,776 | ||
BB yield | -26.62% | -0.80% | -182.74% | ||
| Debt | |||||
Debt current | 60 | 62 | |||
Long-term debt | 650 | 60 | 174 | ||
Deferred revenue | 1,019 | 4,492 | |||
Other long-term liabilities | 7,788 | 7,053 | |||
Net debt | (833,540) | (340,330) | (438,286) | ||
| Cash flow | |||||
Cash from operating activities | (158,564) | (141,218) | 7,972 | ||
CAPEX | (672) | (24) | (13) | ||
Cash from investing activities | (62,848) | (24) | 715 | ||
Cash from financing activities | 659,507 | 8,912 | 375,177 | ||
FCF | (176,860) | (176,416) | 13,346 | ||
| Balance | |||||
Cash | 834,190 | 340,450 | 438,522 | ||
Long term investments | |||||
Excess cash | 831,912 | 339,812 | 433,727 | ||
Stockholders' equity | 17,911 | (302,378) | 484,521 | ||
Invested Capital | 739,791 | 599,638 | 62,457 | ||
ROIC | 44.45% | ||||
ROCE | 2.68% | ||||
| EV | |||||
Common stock shares outstanding | 94,358 | 82,162 | 18,966 | ||
Price | 25.70 130.08% | 11.17 2.48% | 10.90 | ||
Market cap | 2,425,002 164.23% | 917,749 343.93% | 206,732 | ||
EV | 1,591,462 | 577,419 | (231,554) | ||
EBITDA | (176,176) | (176,383) | 13,372 | ||
EV/EBITDA | |||||
Interest | 6,799 | ||||
Interest/NOPBT | |||||